Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran

Title:Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran

Volume: 18 Issue: 3

Author(s): Leila Sadeghi, Samaneh Moallemi, Reza Adl Tabatabai, Ali Esmaeilzadeh, Sara Ahsani-Nasab, Niloofar Eghbal Ahmadi, Saeed Bayanolhagh, Masoomeh Lolaie, Arsalan Narouei, SeyedAhmad SeyedAlinaghi*Minoo Mohraz*

Affiliation:

• Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran,Iran

• Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran,Iran

Keywords: CD4+ Tcell count, Immunological response, Antiretroviral therapy, Vonavir, Zidovudine/ Lamivudine and Efavirenz.

Abstract: Background: The initial antiretroviral therapy (ART) regimens recommended by most national treatment guidelines in resource-limited settings consist of two Nucleoside Reverse-Transcriptase Inhibitors (NRTIs) and one Non-Nucleoside Reverse- Transcriptase Inhibitor (NNRTI). The NRTIs are Zidovudine (AZT) or Stavudine (d4T) with Lamivudine (3TC); the NNRTI components are either Nevirapine (NVP) or Efavirenz (EFV). Existing data regarding the effectiveness of Vonavir compared to other first-line ART regimens in increasing CD4+ T cell counts are unsatisfactory.

Methods: Immunological outcomes of 134 individuals who were on initial stage of antiretroviral therapy with Vonavir or a combination of Zidovudine/Lamivudine and Efavirenz were analyzed. The immunological response was then assessed during 28 weeks.

Results: Both groups demonstrated a significant increase in their CD4+ T cell count which was greater in Zidovudine/Lamivudine and Efavirenz treated group. We observed a noticeable increase in CD4+ T cells rates in the first three months of therapy; however, our results indicated a greater increase of cell counts in individuals with baseline CD4 lower than 100 cells/mm3 treated with Vonavir in first 12 weeks of treatment compared to those with higher baseline CD4.

Conclusion: A rapid CD4+ Tcell increase occurred shortly after beginning ART consisting either Vonavir or combination of Zidovudine, Lamivudine and Efavirenz. Late increases in CD4+ T cell counts were more pronounced in therapy using Zidovudine/ Lamivudine and Efavirenz.

Cite this article as:

Sadeghi Leila , Moallemi Samaneh, Tabatabai Adl Reza , Esmaeilzadeh Ali , Ahsani-Nasab Sara , Ahmadi Eghbal Niloofar , Bayanolhagh Saeed , Lolaie Masoomeh , Narouei Arsalan, SeyedAlinaghi SeyedAhmad *, Mohraz Minoo *, Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran, Infectious Disorders - Drug Targets 2018; 18 (3) . https://dx.doi.org/10.2174/1871526518666180108104031